Grants and Contracts Details
The proposed work aims to develop and refine a new generation of aureolic acid type natural product analogues with significantly diminished toxicity that will be useful as anticancer drugs and/or as drugs to treat neurological diseases, arthritis and hematologic disorders. To enable the production of these fine-tuned drugs through combinatorial biosynthesis or chemo-enzymatic engineering, in-depth research of the biosynthetic machinery of three aureolic acid pathways will be explored, including key enzymes, followed by enzyme reengineering. In addition, based on so far achieved structure-activity-relationship studies, chemoenzymatic approaches for drug derivatization, glycosylation exchange methods and chemoenzymatic glycorandomization techniques will be applied to selectively alter crucial structural features.
|Effective start/end date
|6/1/01 → 6/30/16
- National Cancer Institute: $743,452.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.